SOD1 and amyotrophic lateral sclerosis: More importantly, bosutinib has been shown to increase the survival rate of iPSC‐derived motor neurons in ALS patients with SOD1 mutations [83], and it has been advanced to a phase I dose‐escalation clinical trial for ALS patients [84].